The Metabolic Road to Diastolic Heart Failure: Diastolic Heart Failure Study (MEDIA-DHF)
Primary Purpose
Diastolic Heart Failure
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Blood sampling for biomarker assessment
Sponsored by
About this trial
This is an interventional diagnostic trial for Diastolic Heart Failure
Eligibility Criteria
Inclusion Criteria:
- Patients 18 years of age or older
- Signs or symptoms of HF
- Able and willing to provide freely given written informed consent including analysis of genomics
Exclusion Criteria:
- Patients with acute myocardial infarction
- Recent trauma or surgery (< 3 months)
- Hemodynamically significant valvular disease
- Serious cerebrovascular disease or stroke in the last 3 months
- Chronic dialysis
- Chronic liver disease
- Chronic infectious (bacterial or viral) disease
- Any malignant concomitant diseases or a malignant disease in the last 5 years
- Systemic inflammatory diseases, such as autoimmune diseases, connective tissue diseases or collagenoses
- Pregnant women
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Diastolic heart failure cohort
Arm Description
This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
Outcomes
Primary Outcome Measures
Cardiovascular Hospitalizations or Cardiovascular Death
Secondary Outcome Measures
Cardiovascular Hospitalizations
Heart Failure Hospitalizations
Other cardiovascular hospitalizations
Non cardiovascular hospitalizations
Cardiovascular Death
Non cardiovascular Death
Full Information
NCT ID
NCT02446327
First Posted
April 14, 2015
Last Updated
May 13, 2015
Sponsor
Central Hospital, Nancy, France
1. Study Identification
Unique Protocol Identification Number
NCT02446327
Brief Title
The Metabolic Road to Diastolic Heart Failure: Diastolic Heart Failure Study
Acronym
MEDIA-DHF
Official Title
The Metabolic Road to Diastolic Heart Failure : Diastolic Heart Failure Study (MEDIA-DHF)
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Central Hospital, Nancy, France
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main objective is to replicate the validation of omics biomarkers of left ventricular diastolic dysfunction in patients with metabolic syndrome.
The aim was to recruit overall 750 patients in Europe (100 for France). Currently, 625 patients were enrolled in Europe and 47 in France.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diastolic Heart Failure
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
47 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diastolic heart failure cohort
Arm Type
Other
Arm Description
This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
Intervention Type
Other
Intervention Name(s)
Blood sampling for biomarker assessment
Primary Outcome Measure Information:
Title
Cardiovascular Hospitalizations or Cardiovascular Death
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Cardiovascular Hospitalizations
Time Frame
3 months, 6 months, 12 months
Title
Heart Failure Hospitalizations
Time Frame
3 months, 6 months, 12 months
Title
Other cardiovascular hospitalizations
Time Frame
3 months, 6 months, 12 months
Title
Non cardiovascular hospitalizations
Time Frame
3 months, 6 months, 12 months
Title
Cardiovascular Death
Time Frame
3 months, 6 months, 12 months
Title
Non cardiovascular Death
Time Frame
3 months, 6 months, 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients 18 years of age or older
Signs or symptoms of HF
Able and willing to provide freely given written informed consent including analysis of genomics
Exclusion Criteria:
Patients with acute myocardial infarction
Recent trauma or surgery (< 3 months)
Hemodynamically significant valvular disease
Serious cerebrovascular disease or stroke in the last 3 months
Chronic dialysis
Chronic liver disease
Chronic infectious (bacterial or viral) disease
Any malignant concomitant diseases or a malignant disease in the last 5 years
Systemic inflammatory diseases, such as autoimmune diseases, connective tissue diseases or collagenoses
Pregnant women
12. IPD Sharing Statement
Citations:
PubMed Identifier
32831121
Citation
Stienen S, Ferreira JP, Kobayashi M, Preud'homme G, Dobre D, Machu JL, Duarte K, Bresso E, Devignes MD, Andres NL, Girerd N, Aakhus S, Ambrosio G, Rocca HB, Fontes-Carvalho R, Fraser AG, van Heerebeek L, de Keulenaer G, Marino P, McDonald K, Mebazaa A, Papp Z, Raddino R, Tschope C, Paulus WJ, Zannad F, Rossignol P. Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biol Sex Differ. 2020 Aug 24;11(1):47. doi: 10.1186/s13293-020-00322-7.
Results Reference
derived
Learn more about this trial
The Metabolic Road to Diastolic Heart Failure: Diastolic Heart Failure Study
We'll reach out to this number within 24 hrs